NEW YORK and LONDON, July 13, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing …
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
NEW YORK and LONDON, July 11, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation fromthe European Medicines Agency for Nomacopan for Treatment in HematopoieticStem Cell Transplantation
NEW YORK and LONDON, July 6, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
NEW YORK and LONDON, July 5, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
[Read more...] about Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2023
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL REPORT AND CONSOLIDATED …
